5 P - Is P 53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancers?

Eid, Hanna; Bodrogi, I.; Bak, M.

doi:10.1016/0959-8049(96)84764-2

Cited by 11 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…57 Tumors bearing a p53 wild type gene show higher response to radiotherapy/ chemotherapy, which associates with longer patient survival, while its mutational inactivation leads to lower response and survival in nonsmall cell lung, 64 breast 65 or ovarian 66 carcinoma. In contrast to these results, an increased response in p53 mutant testicular, 67 glioma 68 or bladder 69 tumors has been observed, as compared to p53 wild type tumors. 67 Moreover, and similar to NHEJ proteins, p53 functions in DNA repair as well as in apoptotic regulation, 57 which could lead to contrary outcomes regarding response to genotoxic therapy.…”

Section: <001contrasting

confidence: 49%

“…In contrast to these results, an increased response in p53 mutant testicular, 67 glioma 68 or bladder 69 tumors has been observed, as compared to p53 wild type tumors. 67 Moreover, and similar to NHEJ proteins, p53 functions in DNA repair as well as in apoptotic regulation, 57 which could lead to contrary outcomes regarding response to genotoxic therapy. Therefore, some of the p53 results that have been reported could be unexpected if only the participation of p53 in DNA repair was considered rather than acknowledging a complex and cell-dependent role in DNA repair and apoptosis.…”

Section: <001contrasting

confidence: 49%

See 1 more Smart Citation

Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer

Pavón

Parreño

León

et al. 2008

Intl Journal of Cancer

View full text Add to dashboard Cite

Abstract5‐Fluorouracil and cisplatin‐based induction chemotherapy (IC) is commonly used to treat locally advanced head and neck squamous cell carcinoma (HNSCC). The role of nonhomologous end joining (NHEJ) genes (Ku70, Ku80 and DNA‐PKcs) in double‐strand break (DSB) repair, genomic instability and apoptosis suggest a possible impact on tumor response to radiotherapy, 5‐fluorouracil or cisplatin, as these agents are direct or indirect inductors of DSBs. We evaluated the relationship between Ku80, Ku70 or DNA PKcs mRNA expression in pretreatment tumor biopsies, and tumor response to IC or local recurrence, in 50 patients with HNSCC. Additionally, in an independent cohort of 75 patients with HNSCC, we evaluated the relationship between tumor Ku70 protein expression and the same clinical outcomes or patient survival. Tumors in the responder group had significantly higher mRNA levels for Ku70, Ku80 and DNA‐PKcs than those in the nonresponder group. Ku70 mRNA was the marker most significantly associated with response to IC. Moreover, high tumor Ku70 mRNA expression was associated with significantly longer local recurrence‐free survival (LRFS). Ku70 protein expression was also significantly related to response, and patients with higher percentage of tumor cells expressing Ku70 had longer LRFS. In addition, the percentage of Ku70 positive cells, tumor localization and node involvement were significantly associated with overall survival of patient. Therefore, Ku70 expression is a candidate predictive marker that could distinguish patients who are likely to benefit from chemoradiotherapy or radiotherapy after the induction chemotherapy treatment, suggesting a contribution of the NHEJ system in HNSCC clinical outcome. © 2008 Wiley‐Liss, Inc.

show abstract

Section: <001contrasting

confidence: 49%

Section: <001contrasting

confidence: 49%

Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer

Pavón

Parreño

León

et al. 2008

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Thus one may speculate that there is an interplay between the p53 gene and MT causing MT expression to in¯uence the response to chemotherapy. In an attempt to support the presence of a relationship between these two proteins, we correlated our immunohistochemical results on p53 protein expression, reported elsewhere (Eid et al 1997), with the MT immunostaining results obtained here for the same specimens. We found a very strong positive relationship between MT and p53 immunoreactivity (P 0.0002, Table 5), suggesting that these two gene products are probably not independent of each other.…”

Section: Discussionmentioning

confidence: 95%

Do metallothioneins affect the response to treatment in testis cancers?

Eid

Gergely

Bodrogi

et al. 1998

Journal of Cancer Research and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…In two previous studies, this association appeared to become more significant as the estimated percentage of cells staining positively increased (Dix et al, 1994a); it was shown that IHC detection of p53 protein does not always indicate the existence of an underlying mutation (Dix et al, 1994b). Other studies on non-small-cell lung cancer (Lee et al, 1995), breast cancer (Sjšgren et al, 1996) and testis cancer (Eid et al, 1997) have observed the same unexpected favourable prognosis for patients with high p53 immunostaining. However, the organ and tissue of origin of the tumour seems to have a crucial role in determining overall p53 function.…”

Section: Multivariate Analysesmentioning

confidence: 65%

Expression of high p53 levels in colorectal cancer: a favourable prognostic factor

et al. 1999

View full text Add to dashboard Cite

The relationship between molecular abnormalities and neoplasm has been extensively reviewed and there is strong evidence that abnormalities of p53 gene represent the most common molecular change in human cancer. Such abnormalities can be detected in a number of ways. Several prior studies have revealed p53 protein expression via immunohistochemistry (IHC) in 42Ð69% of colorectal cancers (Scott et al, 1991;Auvinen et al, 1994). However, the prognostic value of this protein remains to be defined, probably due to variability of detection and retrieval systems (Wynford-Thomas, 1994). To be clinically useful, prognostic markers should be accessible to analysis with simple and reproducible procedures appropriate for routine use. We have adapted the recently developed luminometric immunoassay (LIA) (Borg et al, 1995), to quantitate p53 protein in archival colorectal cytosols.The purpose of the present study was: (1) to evaluate the relationship between p53 overexpression and clinicopathological data and (2) to assess the value of p53 as a biological marker of prognosis within each TNM class in a series of patients resected for colorectal cancer with a long follow-up. PATIENTS AND METHODS PatientsA series of 111 patients underwent surgical resection for primary colorectal adenocarcinoma at the II Department of Surgery, University Hospital ÔSan CarlosÕ, Madrid, between 1990 and 1992. Each patient is regularly followed up at 6-monthly intervals for a minimum of 5 years. Cases in which resections have been performed for metachronous carcinoma, carcinoma arising in familial adenomatous polyposis and ulcerative colitis are excluded. None of the patients had received preoperative radiotherapy or chemotherapy. Since 1992, stage III patients younger than 70 received adjuvant chemotherapy with 5-fluorouracil (5-FU) and leucovorin according to the prevailing protocol (four patients). Clinical staging was done on the basis of the TNM classification. Survival time was calculated from the date of surgery to the date of death or last follow-up, with times censored for patients dying of causes unrelated to colorectal cancer and those surviving. Median follow-up was 5 years. Tissue specimensSections from the colorectal adenocarcinoma and normal mucosa at the proximal/distal resection margins were obtained at surgical resection. These specimens were stored in liquid nitrogen and, prior to being pulverized in the frozen state and homogenized for the preparation of cytosols for protein measurement, cryostat sections were evaluated; all tumour samples used contained more than 80% tumour cells. Luminometric assayThe LIA is based on a combination of two monoclonal antibodies, Ab 1801 and DO 1, which detect both wild-type and mutant p53 protein in a sandwich-type assay. The Ab1801, which is immobilized onto a solid phase, is used for catching. Ab DO 1, labelled with a chemiluminescent compound (ABEI), is used for detection. The immunoassay was performed by incubating either 100 µl of p53 standard, controls or tumour cytosols, together with 10...

show abstract

5 P - Is P 53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancers?

Cited by 11 publications

References 0 publications

Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer

Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer

Do metallothioneins affect the response to treatment in testis cancers?

Expression of high p53 levels in colorectal cancer: a favourable prognostic factor

Contact Info

Product

Resources

About